Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 HIV-1 Env antibodies: are we in a bind or going blind?

Literature DB >> 22395694

HIV-1 Env antibodies: are we in a bind or going blind?

John P Moore.

Abstract

Entities: Gene Species

Mesh：

Substances：

Year: 2012 PMID： 22395694 DOI： 10.1038/nm.2689

Source DB: PubMed Journal: Nat Med ISSN： 1078-8956 Impact factor: 53.440

× No keyword cloud information.

13 in total

1. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies.

Authors: J R Mascola; G Stiegler; T C VanCott; H Katinger; C B Carpenter; C E Hanson; H Beary; D Hayes; S S Frankel; D L Birx; M G Lewis
Journal: Nat Med Date: 2000-02 Impact factor: 53.440

2. Moving ahead an HIV vaccine: to neutralize or not, a key HIV vaccine question.

Authors: Thomas J Hope
Journal: Nat Med Date: 2011-10-11 Impact factor: 53.440

Review 3. HIV-1 superinfection and its implications for vaccine design.

Authors: Bhavna H Chohan; Anne Piantadosi; Julie Overbaugh
Journal: Curr HIV Res Date: 2010-12 Impact factor: 1.581

4. AIDS/HIV. A STEP into darkness or light?

Authors: John P Moore; P J Klasse; Matthew J Dolan; Sunil K Ahuja
Journal: Science Date: 2008-05-09 Impact factor: 47.728

5. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody.

Authors: Dennis R Burton; Ann J Hessell; Brandon F Keele; Per Johan Klasse; Thomas A Ketas; Brian Moldt; D Cameron Dunlop; Pascal Poignard; Lara A Doyle; Lisa Cavacini; Ronald S Veazey; John P Moore
Journal: Proc Natl Acad Sci U S A Date: 2011-06-20 Impact factor: 11.205

6. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.

Authors: R Shibata; T Igarashi; N Haigwood; A Buckler-White; R Ogert; W Ross; R Willey; M W Cho; M A Martin
Journal: Nat Med Date: 1999-02 Impact factor: 53.440

7. Safety and efficacy of HIV hyperimmune globulin for prevention of mother-to-child HIV transmission in HIV-1-infected pregnant women and their infants in Kampala, Uganda (HIVIGLOB/NVP STUDY).

Authors: Carolyne Onyango-Makumbi; Saad B Omer; Michael Mubiru; Lawrence H Moulton; Clemensia Nakabiito; Philippa Musoke; Francis Mmiro; Sheryl Zwerski; Hans Wigzell; Lars Falksveden; Britta Wahren; Gretchen Antelman; Mary Glenn Fowler; Laura Guay; J Brooks Jackson
Journal: J Acquir Immune Defic Syndr Date: 2011-12-01 Impact factor: 3.731

8. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial.

Authors: Peter B Gilbert; Michael L Peterson; Dean Follmann; Michael G Hudgens; Donald P Francis; Marc Gurwith; William L Heyward; David V Jobes; Vladimir Popovic; Steven G Self; Faruk Sinangil; Donald Burke; Phillip W Berman
Journal: J Infect Dis Date: 2005-01-27 Impact factor: 5.226

9. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro.

Authors: P W Parren; P A Marx; A J Hessell; A Luckay; J Harouse; C Cheng-Mayer; J P Moore; D R Burton
Journal: J Virol Date: 2001-09 Impact factor: 5.103

10. Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials.

Authors: Peter B Gilbert; James O Berger; Donald Stablein; Stephen Becker; Max Essex; Scott M Hammer; Jerome H Kim; Victor G Degruttola
Journal: J Infect Dis Date: 2011-04-01 Impact factor: 5.226

5 in total

Review 1. Lessons learned from HIV vaccine clinical efficacy trials.

Authors: Tracey A Day; James G Kublin
Journal: Curr HIV Res Date: 2013-09 Impact factor: 1.581

2. Influences on trimerization and aggregation of soluble, cleaved HIV-1 SOSIP envelope glycoprotein.

Authors: Per Johan Klasse; Rafael S Depetris; Robert Pejchal; Jean-Philippe Julien; Reza Khayat; Jeong Hyun Lee; Andre J Marozsan; Albert Cupo; Nicolette Cocco; Jacob Korzun; Anila Yasmeen; Andrew B Ward; Ian A Wilson; Rogier W Sanders; John P Moore
Journal: J Virol Date: 2013-07-03 Impact factor: 5.103

Review 3. Good CoP, bad CoP? Interrogating the immune responses to primate lentiviral vaccines.

Authors: Per Johan Klasse; John P Moore
Journal: Retrovirology Date: 2012-10-01 Impact factor: 4.602

4. A Multiplex Microsphere-Based Immunoassay Increases the Sensitivity of SIV-Specific Antibody Detection in Serum Samples and Mucosal Specimens Collected from Rhesus Macaques Infected with SIVmac239.

Authors: Rebecca L R Powell; Ian Ouellette; Ross W Lindsay; Christopher L Parks; C Richter King; Adrian B McDermott; Gavin Morrow
Journal: Biores Open Access Date: 2013-06

5. HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers.

Authors: Silvia Capucci; Edmund G Wee; Torben Schiffner; Celia C LaBranche; Nicola Borthwick; Albert Cupo; Jonathan Dodd; Hansi Dean; Quentin Sattentau; David Montefiori; Per J Klasse; Rogier W Sanders; John P Moore; Tomáš Hanke
Journal: PLoS One Date: 2017-08-09 Impact factor: 3.240

5 in total